HLB Pep advances US push with vasopressin filing

HLB Pep said Monday that it has registered its vasopressin active pharmaceutical ingredient with the US Food and Drug Administration’s Drug Master File system, advancing its push into global peptide drug markets.

Vasopressin is used to treat septic shock and severe hypotension.

A DMF is a confidential submission detailing an ingredient’s manufacturing process, quality controls and stability, which drugmakers can reference in regulatory applications.

The US registration follows HLB Pep’s registra ...